Abstract library

56 results for "Alternative lengthening of telomeres".
#1186 Significance of ATRX/DAXX Expression and Alternative Lengthening of Telomeres in Insulinomas and Neuroendocrine Tumors of Small Intestine.
Introduction: ATRX and DAXX mutations associated with alternative lengthening of telomeres ( ALT) phenotype have been shown as one of the major altered pathways in pancreatic neuroendocrine tumors (PanNET).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr.med.univ. Bettina Neumayer
#1312 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuro-endocrine tumors (pNETs)
Introduction: DAXX and or ATRX loss occur in 40% of sporadic pNETs. DAXX and ATRX participate in the cell epigenetic status maintenance. Epigenetic changes influence gene expression, function of telomeres and genomic stability. We hypothesize that DAXX/ATRX loss drives tumor progression in pNET through epigenetic changes affecting genomic stability.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ilaria Marinoni
Keywords: DAXX/ATRX, epigenetic, CIN
#856 DAXX and ATRX Loss Defines Chromosomal Instability and Poor Outcome in Pancreatic NET
Introduction: Chromosomal Instability (CIN) has been reported in pancreatic neuroendocrine tumors (pNETs) with poor outcome. However, no specific genetic background has been associated with CIN. Whole exome sequencing revealed mutations in DAXX (Death domain associated protein gene) and ATRX (ATR-X gene) in 40% of pNETs. DAXX and ATRX mutations in pNETs are associated with Alternative Lengthening of Telomeres (ALT) activation.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Ilaria Marinoni
Keywords: pNET, Daxx, Atrx, ALT, CIN
#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Dr. Mauro Cives
#357 Alternative Splicing and Differential Gene Expression in Pancreatic NETs
Introduction: Alternative splicing is an important mechanism to increase diversity of the proteome in higher organisms. These protein isoforms can provide as a selective drug target or marker for cancer diagnosis.
We present here a new DNA array that allows identification of splice variation and differential expression of 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.
Conference:
Category: Basic
Presenting Author: Jan Lennart Körner
#529 Alternative Splicing and Differential Gene Expression in Pancreatic NETs
Introduction: Protein isoforms resulting from differentially spliced mRNA may constitute peculiar drug targets or markers for cancer diagnosis. We here present a new DNA array that allows identification of splice variation and differential expression for 357 G protein-coupled receptors (GPCR) and 11 proteins of the extracellular matrix.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Carsten Grötzinger
Keywords: pNET
#1813 Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response
Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Angela Lamarca
Keywords: sunitinib, RECIST, cut-off
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#1945 Metabolic Adaptation to Anti-Angiogenic Therapy
Introduction: Although anti-angiogenic inhibition (AI) therapy has demonstrable efficacy in mouse models of cancer and in certain types of human cancer, responses are typically transitory, followed by resumption of malignant progression that limits survival benefit. Unconventional modes of evasive/adaptive resistance underlay the eventual failures of anti-angiogenic therapy. Functionally established resistance mechanisms include revascularization mediated by alternative pro-angiogenic signals, protection by peri-vascular macrophages and monocytes to induce an immunosuppressive microenvironment, and normal vessel cooption via heightened local invasion and distant metastasis. All three mechanisms have been documented in the prototypical RIP-Tag2 mouse model of multistep tumorigenesis, in which the angiogenic switch is a discrete step in the pathway to invasive pancreatic neuroendocrine cancer.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Elizabeth Allen
Authors: Allen E, ...
Keywords: AI/mTOR
#192 Successfull Endoscopic Ultrasound-Guided Alcoholic Ablation of Insulinoma
Introduction: Insulinomas are rare endocrine tumors. The golden treatment is surgical resection. EUS-guided alcohol ablation is a new promising method to treat those patients who are not surgical candidates.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christina Schnack
Authors: schnack C, Hansen C, Nielsen H, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.